Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
نویسندگان
چکیده
منابع مشابه
The Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke. Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran. Materials & Methods: In this retrosp...
متن کاملEligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study.
BACKGROUND AND PURPOSE Acute ischemic stroke patients are infrequently treated with recombinant tissue plasminogen activator (rtPA). We present unique population-based data regarding the eligibility of ischemic stroke patients for rtPA treatment. METHODS All ischemic strokes presenting to an emergency department (ED) within a biracial population of 1.3 million were identified. The patient was...
متن کاملpharmacotherapy updates of recombinant tissue plasminogen activator (r-tpa) in acute ischemic stroke
conclusions due to considerable inter- and intra- heterogeneity among studies performed by other centers such as differences in study project, background, and population features, determining a pharmacotherapy model based on safe implementation of treatments in stroke or sits seem advantageous. results age, time of onset, systolic blood pressure, diabetes, stroke severity, co-morbidities and pr...
متن کاملRecombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke
THE FOOD AND DRUG ADMINIStration (FDA) approval in June 1996 of intravenous recombinant tissue-type plasminogen activator (rt-PA) for patients with acute ischemic stroke treated within 3 hours of symptom onset marked a historic first step in treating this devastating disease. This approval was primarily based on the results of the National Institute of Neurologic Disorders (NINDS) trials (1 and...
متن کاملAcute Ischemic Stroke After Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction
Introduction/Background: Occurrence of a cerebrovascular accident (CVA) after thrombolytic therapy for acute myocardial infarction (MI) is an uncommon but recognized clinical problem [1]. Although, intracranial hemorrhage is the primary neurological complication noted after thrombolytic therapy [2, 3], ischemic CVA is an infrequent and devastating complication that is reported to occur after 48...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2004
ISSN: 0039-2499,1524-4628
DOI: 10.1161/01.str.0000109767.11426.17